Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Curis Inc (CRIS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 51,652
  • Shares Outstanding, K 33,110
  • Annual Sales, $ 9,900 K
  • Annual Income, $ -53,320 K
  • 36-Month Beta 1.16
  • Price/Sales 5.59
  • Price/Cash Flow N/A
  • Price/Book 70.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.21
  • Low Estimate -0.22
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +12.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.45 unch
on 11/12/18
2.37 -38.82%
on 10/16/18
-0.44 (-23.28%)
since 10/12/18
3-Month
1.36 +6.62%
on 08/21/18
2.37 -38.82%
on 10/16/18
-0.16 (-9.94%)
since 08/10/18
52-Week
1.36 +6.62%
on 08/21/18
6.05 -76.03%
on 11/13/17
-4.70 (-76.42%)
since 11/10/17

Most Recent Stories

More News
Curis to Present at 33rd Society for Immunotherapy of Cancer Annual Meeting and Cowen IO NEXT Summit

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced upcoming presentations at the...

CRIS : 1.45 (-7.05%)
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of 29.03% and 19.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CRIS : 1.45 (-7.05%)
Curis: 3Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Thursday reported a loss of $7.2 million in its third quarter.

CRIS : 1.45 (-7.05%)
Curis to Release Third Quarter Financial Results and Hold Conference Call on November 1, 2018

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that the Company will release...

CRIS : 1.45 (-7.05%)
Investor Expectations to Drive Momentum within Ormat Technologies, The Andersons, Freshpet, Curis, Ultra Clean, and Edge Therapeutics -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ormat Technologies, Inc....

ANDE : 32.67 (-0.94%)
FRPT : 36.35 (+0.47%)
CRIS : 1.45 (-7.05%)
UCTT : 8.78 (-7.48%)
EDGE : 0.67 (-4.29%)
ORA : 52.05 (-1.72%)
Is a Beat in Store for Vertex (VRTX) This Earnings Season?

On Vertex' (VRTX) third-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.

CRSP : 36.17 (-0.55%)
CRIS : 1.45 (-7.05%)
VRTX : 172.85 (-4.26%)
AMGN : 191.56 (-0.83%)
Curis (CRIS) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Curis, Inc. (CRIS).

CRIS : 1.45 (-7.05%)
Increasing Number of Cancer Cases to Fuel the Global Cancer Immunotherapy Market Growth

According to data compiled by Transparency Market Research, the global cancer immunotherapy market is expected to grow from USD 37.50 Billion in 2015 to USD 124.88 Billion by 2024 while registering a CAGR...

RGBP : 0.0060 (+5.26%)
CRIS : 1.45 (-7.05%)
BPTH : 0.45 (unch)
ATHX : 1.90 (+1.60%)
BLRX : 0.68 (-2.86%)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that on October 1, 2018, the...

CRIS : 1.45 (-7.05%)
Curis to Present at the Cantor Fitzgerald Global Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company...

CRIS : 1.45 (-7.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CRIS with:

Business Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate...

See More

Key Turning Points

2nd Resistance Point 1.60
1st Resistance Point 1.52
Last Price 1.45
1st Support Level 1.41
2nd Support Level 1.38

See More

52-Week High 6.05
Fibonacci 61.8% 4.26
Fibonacci 50% 3.71
Fibonacci 38.2% 3.15
Last Price 1.45
52-Week Low 1.36

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar